Abstract: Disclosed are various embodiments for a parallel priority queue implemented on one or more many-core processors and/or multi-core processors such as those in general-purpose graphics processing units (GPGPUs). According to various embodiments, a priority may be determined according to a timestamp of an item, such as an event or an entry, in a priority queue. A priority queue interface may comprise functions to insert and remove entries from the priority queue. Priority order of the entries may be maintained as the entries are inserted and removed from the queue.

Abstract: Modulators of Wnt activity, e.g., Wnt inhibitors, that act on TIKI proteins and inhibit TIKI-mediated cleavage of Wnt proteins, as well as methods of identifying such modulators and methods of use thereof.

Abstract: Methods and kits for expanding a stem cell population, particularly a hematopoietic stem cell population, in the presence of a DNA methyltransferase modulator and a Wnt pathway modulator are disclosed.

Abstract: One embodiment of the present invention sets forth a technique for detecting a video transition. The technique involves calculating a first average pixel intensity for each pixel grouping included in a first plurality of pixel groupings, calculating a second average pixel intensity for each pixel grouping included in a second plurality of pixel groupings, and calculating a third average pixel intensity for each pixel grouping included in a third plurality of pixel groupings. The technique further involves comparing a first average pixel intensity to a corresponding second average pixel intensity to identify a first trend, comparing a second average pixel intensity to a corresponding third average pixel intensity to identify a second trend, and comparing the first trend to the second trend to determine whether a match exits. Finally, the technique involves determining that a video transition is occurring based on a number of matches.

Abstract: A composite catalyst, including: a) dispersed and cationic surface modifier-modified attapulgite as a catalyst carrier; and b) nano-Au as an active ingredient. The nano-Au accounts for 0.5-1.5 wt. % of the attapulgite. An average diameter of the attapulgite is 18-22 nm, and a length thereof is 100-1000 nm. A particle diameter of the nano-Au is 1-7 nm. The composite catalyst has a low activation temperature and high performance-to-price ratio, and can be used for oxidation of organic pollutants in waste gas under low temperatures and also has excellent catalytic effects on organic pollutants in waste fluid. A preparation method of the composite catalyst is also provided.

Abstract: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine ?-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.

Abstract: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine ?-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.

Abstract: This invention relates to Tiki1 and Tiki2 proteins and nucleic acids, cells expressing the same, and methods for identifying compounds that modulate Tiki1/2 activity for use in the treatment of osteoporosis or cellular proliferative disorders.

Abstract: In various embodiments, a high frequency transformer is provided. The high frequency transformer may include a magnetic core; a primary winding; and a plurality of secondary windings; wherein the plurality of secondary windings and the primary winding are arranged separately, and each secondary winding constitutes a parasite current transformer with the primary winding.

Abstract: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine ?-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.

Abstract: An exemplary plastic coated edge structure (10) includes a base sheet (11) and a protective plastic layer (12). A fringe portion of the base sheet defines a plurality of through holes (15). The protective plastic layer coats the fringe portion, and part of the protective plastic layer engages in the through holes. A method for making a plastic coated edge structure includes: providing a base sheet including a fringe portion, the fringe portion defining a plurality of though holes; putting the base sheet into an injection mold; injecting a melted plastic material into the injection mold from a side of the fringe portion to an opposite side of the fringe portion from the through holes to form the protective plastic layer for coating the fringe portion; solidifying the plastic material to form a plastic coated edge structure; and taking the plastic coated edge structure out of the injection mold.

Abstract: A LED lighting arrangement includes a support body having mounted thereon one or more LED lighting sources and a driver or feeding the LED lighting sources. The support body includes a high-voltage section carrying the driver and a low-voltage section carrying, mounted on a heat sink, the light sources. An insulation barrier is provided between the high voltage section and the low-voltage section of the board with a twisted pair forming a wiring that traverses the insulation barrier to connect the driver and the LED lighting sources.

Abstract: The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.

Abstract: The present invention relates to mutant BMP intestinal stem cells (ISCs), with these mutant ISCs possessing an inactive Bmpr1a receptor in which BMP binding is substantially inhibited. The present invention relates to vectors which comprise mutant Bmpr1a nucleic acid sequences, whereby the vectors can be used to promote an increase in the number of ISCs in vivo or in vitro.

Abstract: Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

Abstract: The present invention relates to mutant BMP intestinal stem cells (ISCs), with these mutant ISCs possessing an inactive Bmpr1a receptor in which BMP binding is substantially inhibited. The present invention relates to vectors which comprise mutant Bmpr1a nucleic acid sequences, whereby the vectors can be used to promote an increase in the number of ISCs in vivo or in vitro.

Abstract: A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.

Abstract: The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.

Abstract: The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.